相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
33.3%
终止
1
33.3%
暂无批准数据
- Abbott has received US FDA approval for the TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy device for treating challenging cases of atrial fibrillation. - The catheter allows physicians to deliver pulsed field ablation, radiofrequency energy, or a combination of both during a single procedure to tailor treatment. - Approval was based on the FlexPulse IDE study, whose late-breaking data showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib. - The approval marks Abbott's fifth major electrophysiology approval in just over a year, following the Volt PFA System and other clearances.
- Quebec has released its inaugural Politique québécoise en médecine génomique, a framework for ethical, equitable, and sustainable expansion of genomic medicine province-wide. - The policy establishes standards, infrastructure, and coordination to move genomic testing from specialized centers into routine clinical practice across Quebec. - Clinicians will be better equipped to anticipate disease risk, refine diagnoses, and deliver personalized treatments based on patients' molecular and genomic characteristics. - The framework addresses workforce training, laboratory capacity, equitable access to genomic services, and patients' rights regarding hereditary risk information.
- The landmark SNAP trial, involving 1,341 patients across eight countries, demonstrated cefazolin is at least as effective as flucloxacillin for MSSA bloodstream infections, with 90-day mortality of 15% versus 17%. - Cefazolin was associated with significantly fewer cases of acute kidney injury (14%) compared with flucloxacillin (20%), establishing a superior safety profile. - Researchers and clinicians now recommend cefazolin as the new first-line standard of care for most adults with methicillin-susceptible S. aureus bacteremia. - The findings, published in the New England Journal of Medicine, represent the largest randomized trial ever conducted for S. aureus bloodstream infections and challenge decades of clinical practice.
- A prospective study of nearly 5,000 men with nonmetastatic prostate cancer found that the type and source of dietary fat after diagnosis was associated with long-term survival over a median 12.8 years of follow-up. - Men with the highest saturated-fat intake had a 24% higher rate of death, and replacing 10% of daily calories from animal fat with plant-based fat was linked to a 16% lower all-cause mortality rate. - The associations were driven primarily by cardiovascular deaths and other cancers, not prostate cancer itself, underscoring the importance of cardiovascular health in survivorship care. - Researchers emphasize simple substitutions—such as choosing olive oil, nuts, seeds, and avocados—rather than restrictive diets, while cautioning that the findings show association, not causation.
- Two major trials involving 4,232 participants found that Paxlovid does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster. - The UK PANORAMIC trial showed median recovery time of 14 days with Paxlovid versus 21 days with usual care, while the Canadian CanTreatCOVID trial found recovery at 6 days versus 9 days respectively. - Hospitalization rates remained very low in both trials, with no statistically significant differences between Paxlovid and usual care groups across either study. - These findings provide crucial evidence for cost-effective targeting of Paxlovid treatment in today's highly vaccinated populations where severe COVID-19 outcomes are already rare.
- The COBRRA trial found that apixaban reduced bleeding risk by more than half compared to rivaroxaban in 2,760 patients with acute venous thromboembolism over three months. - Clinically relevant bleeding occurred in 3.3% of apixaban patients versus 7.1% of rivaroxaban patients, with no significant difference in blood clot recurrence rates. - Despite higher medication adherence with rivaroxaban (75.1% vs 65.7%), the safety advantage of apixaban remained consistent across the international study. - The findings provide the first head-to-head comparison of these commonly prescribed anticoagulants and may influence clinical practice guidelines for venous thrombosis treatment.
- Two phase 1-2 clinical trials demonstrate that fecal microbiota transplantation (FMT) combined with immune checkpoint inhibitors achieves impressive response rates of 80% in non-small cell lung cancer and 75% in melanoma patients. - FMT from healthy donors successfully engrafts beneficial bacteria while eliminating harmful species from patients' baseline microbiomes, with bacterial loss being more predictive of treatment response than donor strain acquisition. - Safety profiles vary significantly by treatment regimen, with dual checkpoint inhibition showing earlier onset of severe adverse events, particularly when patients receive FMT from Prevotella-rich donors. - Metabolomic analysis reveals that treatment responders maintain lower levels of immunosuppressive tryptophan pathway metabolites, suggesting FMT helps preserve an immune-permissive environment for cancer therapy.
- Health Canada has granted approval for LOQTORZI (toripalimab), marking the first and only immunotherapy approved for patients with recurrent unresectable or metastatic nasopharyngeal carcinoma. - The therapy is indicated both as combination treatment with cisplatin and gemcitabine for metastatic or recurrent locally advanced disease, and as monotherapy for patients who have progressed following platinum-based chemotherapy. - This approval represents Apotex's first novel biologic therapy and addresses a critical unmet medical need for patients facing this ultra-rare and aggressive cancer. - The Canadian pharmaceutical company secured rights to LOQTORZI through an agreement with Coherus BioSciences, expanding access to innovative oncology treatments in Canada.
- A Phase 1 clinical trial of budigalimab, an anti-PD-1 monoclonal antibody, demonstrated safety and potential for long-term HIV control without daily antiretroviral therapy. - Six of eleven participants who received treatment in stage 2 experienced delayed viral rebound, with two maintaining viral suppression for over six months after stopping ART. - The low-dose immunotherapy approach targets the PD-1 pathway to re-energize exhausted T cells, potentially enabling the immune system to control HIV independently. - Results suggest some participants maintained viral control even after the drug was no longer detectable, indicating possible immune system enhancement rather than direct viral suppression.
- Adagio Medical's FULCRUM-VT pivotal study demonstrated 97.4% acute clinical success in treating sustained monomorphic ventricular tachycardia using proprietary ultra-low temperature cryoablation technology. - The study enrolled 207 patients with both ischemic and non-ischemic cardiomyopathy across 19 sites, completing enrollment in just 11 months despite historically slow VT ablation study recruitment. - Major adverse events occurred in 2.5% of patients, with one device-related death (0.5%), while 96.7% of patients had all clinically-relevant ventricular tachycardias eliminated. - The vCLAS System represents the first VT-specific ablation technology to complete pivotal IDE study enrollment in the United States, with PMA approval anticipated by year-end 2026.
